Celltrion is expanding its global partnerships by showcasing its next-generation drug development capabilities at the 2026 Bio International Convention (BioUSA), the world's largest biotechnology exhibition. The company is broadening its business scope beyond biosimilars to include antibody-drug conjugates (ADCs), multi-antibodies, and AI-based drug development, highlighting its potential for future growth.
According to Celltrion, the company held over 180 business meetings with global pharmaceutical companies, biotech firms, and investors during the event, which took place in San Diego from June 22 to 25. This marks the highest number of meetings since Celltrion began participating in BioUSA, with both corporate meetings and booth visitors reaching record levels.
Having participated in the event since 2010, Celltrion sent teams specializing in ADCs and multi-antibody drugs this year to explore joint development and technological collaboration opportunities with various global companies.
The company also actively showcased its achievements and capabilities in AI technology, drawing significant interest. Key highlights included AI-based target discovery, portfolio expansion, next-generation multi-antibody design technology, in silico developability assessment, and a data-driven research platform known as the Healthcare Intelligence Bank.
In the field of materials and components, Celltrion discussed collaboration strategies with global companies to enhance product manufacturing efficiency and technological capabilities, with plans for follow-up discussions after the event. This year, the number of visitors to the Celltrion booth exceeded 2,000, setting a new record.
A Celltrion representative stated, "This year at BioUSA, we confirmed heightened interest and recognition for Celltrion with over 180 business meetings and more than 2,000 attendees. Notably, interest in our next-generation growth drivers, including ADCs, multi-antibodies, and AI-based technologies, is at an all-time high."
BioUSA is the largest biotechnology industry event globally, featuring participation from over 1,500 pharmaceutical and biotech companies, investors, and research institutions. Each year, it attracts more than 20,000 industry professionals for discussions on technology transfer, investment, and joint development.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.